Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
|Videos|April 10, 2022
Available Atopic Dermatitis Therapies for Pediatric Patients
Author(s)Miranda Hester
Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, expands on his AD overview from the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference is being held from April 9 to 11 in Baltimore, Maryland.
Advertisement
Robert Sidbury, MD, MPH, the division chief of dermatology at Seattle Childrens, talks the best which medications are best used for mild-to-moderate AD vs moderate-to-severe AD in pediatric patients and more in this video interview.
Advertisement
Related to this article
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
Advertisement
Advertisement
Trending on Dermatology Times
1
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
2
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
3
GLP-1 Candidacy and Prescribing Considerations in Psoriasis
4
JAK Inhibitors for Alopecia Areata: Selectivity and Pivotal Trial Efficacy
5